Literature DB >> 23049131

Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

M Rosenblum1, M J Van der Laan.   

Abstract

It is a challenge to evaluate experimental treatments where it is suspected that the treatment effect may only be strong for certain subpopulations, such as those having a high initial severity of disease, or those having a particular gene variant. Standard randomized controlled trials can have low power in such situations. They also are not optimized to distinguish which subpopulations benefit from a treatment. With the goal of overcoming these limitations, we consider randomized trial designs in which the criteria for patient enrollment may be changed, in a preplanned manner, based on interim analyses. Since such designs allow data-dependent changes to the population enrolled, care must be taken to ensure strong control of the familywise Type I error rate. Our main contribution is a general method for constructing randomized trial designs that allow changes to the population enrolled based on interim data using a prespecified decision rule, for which the asymptotic, familywise Type I error rate is strongly controlled at a specified level α. As a demonstration of our method, we prove new, sharp results for a simple, two-stage enrichment design. We then compare this design to fixed designs, focusing on each design's ability to determine the overall and subpopulation-specific treatment effects.

Entities:  

Year:  2011        PMID: 23049131      PMCID: PMC3413180          DOI: 10.1093/biomet/asr055

Source DB:  PubMed          Journal:  Biometrika        ISSN: 0006-3444            Impact factor:   2.445


  16 in total

1.  Adaptive sample size calculations in group sequential trials.

Authors:  W Lehmacher; G Wassmer
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

2.  Sequential designs for phase III clinical trials incorporating treatment selection.

Authors:  Nigel Stallard; Susan Todd
Journal:  Stat Med       Date:  2003-03-15       Impact factor: 2.373

3.  Estimation in flexible two stage designs.

Authors:  Werner Brannath; Franz König; Peter Bauer
Journal:  Stat Med       Date:  2006-10-15       Impact factor: 2.373

4.  Testing and estimation in flexible group sequential designs with adaptive treatment selection.

Authors:  Martin Posch; Franz Koenig; Michael Branson; Werner Brannath; Cornelia Dunger-Baldauf; Peter Bauer
Journal:  Stat Med       Date:  2005-12-30       Impact factor: 2.373

Review 5.  Adaptive seamless designs: selection and prospective testing of hypotheses.

Authors:  Christopher Jennison; Bruce W Turnbull
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

6.  Evaluating treatments when a gender by treatment interaction may exist.

Authors:  E Russek-Cohen; R M Simon
Journal:  Stat Med       Date:  1997-02-28       Impact factor: 2.373

7.  Evaluation of experiments with adaptive interim analyses.

Authors:  P Bauer; K Köhne
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

8.  Repeated confidence intervals for group sequential clinical trials.

Authors:  C Jennison; B W Turnbull
Journal:  Control Clin Trials       Date:  1984-03

Review 9.  Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.

Authors:  J Baselga
Journal:  Oncology       Date:  2001       Impact factor: 2.935

10.  Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.

Authors:  Sue-Jane Wang; Robert T O'Neill; H M James Hung
Journal:  Pharm Stat       Date:  2007 Jul-Sep       Impact factor: 1.894

View more
  16 in total

1.  Social science. Promoting transparency in social science research.

Authors:  E Miguel; C Camerer; K Casey; J Cohen; K M Esterling; A Gerber; R Glennerster; D P Green; M Humphreys; G Imbens; D Laitin; T Madon; L Nelson; B A Nosek; M Petersen; R Sedlmayr; J P Simmons; U Simonsohn; M Van der Laan
Journal:  Science       Date:  2014-01-03       Impact factor: 47.728

2.  Recursive partitioning for heterogeneous causal effects.

Authors:  Susan Athey; Guido Imbens
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

3.  Using Bayesian modeling in frequentist adaptive enrichment designs.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

4.  Adaptive enrichment designs for clinical trials.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2013-03-21       Impact factor: 5.899

5.  Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children.

Authors:  David Schnadower; Phillip I Tarr; T Charles Casper; Marc H Gorelick; J Michael Dean; Karen J O'Connell; Prashant Mahajan; Adam C Levine; Seema R Bhatt; Cindy G Roskind; Elizabeth C Powell; Alexander J Rogers; Cheryl Vance; Robert E Sapien; Cody S Olsen; Melissa Metheney; Viani P Dickey; Carla Hall-Moore; Stephen B Freedman
Journal:  N Engl J Med       Date:  2018-11-22       Impact factor: 91.245

Review 6.  Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations.

Authors:  Maya Petersen; Constantin T Yiannoutsos; Amy Justice; Matthias Egger
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

7.  Uniformly Most Powerful Tests for Simultaneously Detecting a Treatment Effect in the Overall Population and at Least One Subpopulation.

Authors:  Michael Rosenblum
Journal:  J Stat Plan Inference       Date:  2014-07-10       Impact factor: 1.111

8.  Inference for multimarker adaptive enrichment trials.

Authors:  Richard Simon; Noah Simon
Journal:  Stat Med       Date:  2017-08-10       Impact factor: 2.373

9.  Testing for efficacy in adaptive clinical trials with enrichment.

Authors:  Samuel S Wu; Yi-Hsuan Tu; Ying He
Journal:  Stat Med       Date:  2014-02-27       Impact factor: 2.373

10.  Confidence intervals for the selected population in randomized trials that adapt the population enrolled.

Authors:  Michael Rosenblum
Journal:  Biom J       Date:  2013-04-03       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.